Executive Leadership Team

The Executive Leadership Team (ELT) is responsible for setting and influencing Genomics England’s strategic direction (with the Board); defining, delivering and evaluating Genomics England’s activities: providing leadership, both inside the organisation and externally as ambassadors and thought leaders.

Chris joined Genomics England as CEO in October 2019, excited by the mission to use genomic data and advanced analytical techniques to transform the health of millions of people around the world. He heads up our executive team while working with our Board, our patient participants, and our many partners in the NHS, the wider healthcare sector and the tech world to improve patient outcomes while lowering the cost of healthcare provision.

Prior to his appointment at Genomics England, Chris was COO at QuantumBlack, a bespoke machine learning and AI technology company, and a Partner at McKinsey working on technology strategy topics.

He previously worked for the UK Foreign Office (where he led analytical work at the Counter Terrorism Policy Department), and at the BBC (transitioning to digital broadcasting and iPlayer). He has held board roles at the New Entrepreneurs Foundation, Entrepreneur First and Magic Breakfast.

Chris lives in London with his wife Tara and their three children, and loves nothing more than a winter’s day climbing a snowy mountain followed by a nice dinner with a glass of Italian red wine.

In 2013 Sir Mark Caulfield was appointed Chief Scientific Officer for Genomics England, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. The Chief Scientific Officer’s team lead on all scientific activities for Genomics England.

Sir Mark engages with NHS scientific teams and the general public to promote, explains and enthuses about the 100,000 Genomes Project, and oversees the Clinical Interpretation Partnership and Access Review Committee. He is also responsible as Head of Profession (Science and Clinical) for helping us attract and retain the best scientific and clinical talent to the Project and ensuring our clinician community can develop professionally and appropriately within the Project.

Our Ethics team is also part of the Chief Scientific Officer’s team, supporting Genomics England in its ethical governance of the Project, working in line with participants’ consent, the Project’s aims and advising on compliance with relevant medical, academic and data legislation, regulation including Research Ethics Committee (REC) approval, professional guidance and good ethical practice. This includes seeking input from patient groups and Project participants. The Ethics team leads on ethical policy issues, and provides the secretariat for the Ethics Advisory Committee and its standing subgroups on Equalities, Consent and Legacy (the future of mainstreamed NHS genomics beyond the Project).

Read more about Professor Sir Mark Caulfield

In January 2019, Sir Mark was appointed interim Chief Executive at Genomics England until October, and in June received a knighthood in the 2019 Queen’s Birthday Honours in recognition of his services to the 100,000 Genomes Project.

Nick is an experienced and award winning commercial and procurement lawyer particularly in the health, transport and education sectors.

He is responsible for all legal activity within Genomics England including ensuring that the organisation complies with the law (Data Protection, Freedom of Information, Human Tissues Act) and the Company’s Articles and policies.

He is also responsible for signing off all procurement and contracting work.

Prior to his role at Genomics England, Nick was a partner in three Top 100 law firms: Pinsent Masons, DLA Piper and Bircham Dyson Bell.

Anna has over 20 years’ professional experience in communications at global and national levels in a number of sectors, including healthcare and professional services. She is accomplished at managing complex, integrated communication initiatives and has a proven track record in corporate reputation management, media relations, issues and crisis management, internal communications, executive and change communications.

Anna’s team is responsible for all internal and external-facing communications, reputation management and engagement strategies at Genomics England. The team works closely with participants and other stakeholders, including the Department of Health and Social Care, the Office for Life Sciences, NHS England, commercial partners and academic communities.

Anna holds a degree from Cambridge University, and began her career in investment banking. She joined Genomics England in 2019, and prior to this she held roles including Global Communications Director at US health giant, Aetna, and Group Marketing and Communications Director at InHealth Group.

Augusto is seconded from the University of Cambridge Department of Haematology, and leads over 70 developers, analysts, bioinformaticians and curators at Genomics England. His team is responsible for establishing pipelines to analyse and manage all genomic data for the 100,000 Genomes Project and the new NHS Genomic Medicine Service.

Augusto and his team have designed and implemented the clinical interpretation pipelines that return findings to patients, while ensuring that knowledge accumulated through this process is best used to improve patient care and enhance discovery.

Parker is responsible for Genomics England’s strategic relationships in the biopharma sector, the NHS and academia. Previously Parker served as a member of the executive team at Owkin, an AI/ML Cancer Research company focussed on federated learning. He was a CTO in the NHS, including technology leadership roles at Great Ormond Street and Virgin Care. He worked at F-Prime and EightRoads, Fidelity-backed VC funds and led the investment in Owkin before joining the company. Parker also holds several non-executive roles, including Membership on the Secretary of State’s technology advisory board, and member of Cancer Research UK’s commercial board. Parker holds a degree in Physics and Philosophy from Durham University. Outside of work his passion is classical music.


Rakhi joined Genomics England as CDO in May 2020 to drive innovation in healthcare products and services that put the patient and society at the core.  She was previously an Associate Partner at QuantumBlack and McKinsey where she led global foresight and human-centred AI projects. Prior to that Rakhi has held senior innovation positions at startups and large organisations spanning emerging tech, healthcare, aerospace and defence, hospitality, and automotive. She is a Chartered Psychologist and holds degrees in Psychology, Engineering and Design.

Catherine has over sixteen years’ experience in government, working in the Department of Health and Social Care, the Office for Lifesciences, in Cabinet Office and with No10. Most recently Catherine was Head of NHS Finance at DHSC from 2016-2019, and led on Lab Capacity in the DHSC Covid19 Testing Programme in Spring 2020. She also has experience of Genomics England, having worked with the organisation in 2014 during the 100,000 Genomes Project. Catherine brings a wealth of expertise in government finance, policy, programme management, governance and stakeholder management.

As Chief Transformation Officer, Catherine leads the finance, estates, quality and performance chapters at GEL. She will be working closely with all of the ELT and our new Tribes to embed our transformation and deliver on our new strategy.

Catherine lives in Essex with her husband and three children, and spends her spare time going for long walks in Epping Forest and cooking for family and friends.

Dr Richard Scott joined the organisation in 2015. He is also a Consultant and Honorary Senior Lecturer in Clinical Genetics at Great Ormond Street Hospital for Children and the UCL Institute of Child Health where his practice focuses on diagnosing children with rare multisystem disorders.

Richard trained in medicine at Cambridge University and University College London. He specialised in Paediatrics and subsequently Clinical Genetics in London and completed his PhD on childhood cancer syndromes at the Institute of Cancer Research.

Through his clinical practice and in his role at Genomics England he is passionate about harnessing the power of new genomic technologies for the benefit of patients in mainstream healthcare.